Entera Bio (ENTX) Director Sean Ellis Receives Share Award & Options

What Happened

• Sean Ellis, a director of Entera Bio Ltd. (ENTX), was awarded 20,034 ordinary shares and granted fully vested options to purchase 40,000 ordinary shares. Both transactions were reported on 2026-08-07 and were recorded at $0.00 (awards/options issued, not purchases or sales). The 20,034 shares were issued in lieu of cash director fees for Q1 and Q2 2026; the 40,000-item is an option grant (derivative), not an exercised sale.

Key Details

• Transaction date: 2026-08-07; Price reported: $0.00 for both items (award and derivative option grant).
• Award: 20,034 ordinary shares issued in lieu of cash director fees (Board approved Aug 5, 2026; registration on Form S-8 filed Aug 7, 2026).
• Option grant: fully vested options to purchase 40,000 ordinary shares (Board approved May 7, 2026; shareholder approval obtained July 14, 2026; Form S-8 registering underlying shares filed Aug 7, 2026).
• Shares owned after the transaction: not specified in the provided filing excerpt.
• Filing: Form 4 filed with the SEC on 2026-08-07 (registration on Form S-8 occurred same day).

Context

• The 20,034-share award replaces cash director fees and should be viewed as compensation, not a market purchase signal.
• The 40,000-share item is a grant of fully vested options (a derivative grant) — it does not indicate an exercise or sale; exercise would be a separate transaction if/when it occurs.
• These are routine director compensation and board-approved equity grants; no indication of a 10% owner transaction or a 10b5-1 sale plan in the filing.